New York State Teachers Retirement System Grows Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

New York State Teachers Retirement System grew its position in Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report) by 1.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,500 shares of the medical research company’s stock after acquiring an additional 200 shares during the quarter. New York State Teachers Retirement System owned about 0.06% of Bio-Rad Laboratories worth $4,262,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GeoWealth Management LLC lifted its position in shares of Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. Picton Mahoney Asset Management lifted its position in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 35 shares in the last quarter. Curat Global LLC purchased a new position in shares of Bio-Rad Laboratories in the first quarter valued at approximately $34,000. Brown Brothers Harriman & Co. lifted its position in shares of Bio-Rad Laboratories by 2,928.6% in the fourth quarter. Brown Brothers Harriman & Co. now owns 212 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 205 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $71,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. UBS Group cut their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Wells Fargo & Company cut their price target on Bio-Rad Laboratories from $260.00 to $245.00 and set an “equal weight” rating for the company in a report on Monday, June 9th. Citigroup cut their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Wall Street Zen raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Royal Bank Of Canada cut their price target on Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and an average price target of $324.25.

View Our Latest Research Report on Bio-Rad Laboratories

Bio-Rad Laboratories Price Performance

BIO stock opened at $251.56 on Monday. The business has a fifty day moving average of $235.85 and a two-hundred day moving average of $271.37. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of -3.30 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIOGet Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 4.32% and a negative net margin of 85.16%. The business had revenue of $585.40 million during the quarter, compared to analysts’ expectations of $573.01 million. During the same period in the previous year, the firm posted $2.30 earnings per share. The company’s revenue was down 4.2% on a year-over-year basis. As a group, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Profile

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Read More

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.